Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Veteran Haggar To Lead Private Equity-Backed Zentiva From Next Month

Executive Summary

Only four months after it was carved out from Sanofi to become an independent company, Prague-based Zentiva has announced fresh leadership in the form of Nick Haggar, the 30-year industry veteran and former president of Medicines of Europe.

You may also be interested in...



Zentiva Snaps Up Alvogen’s CEE Operations

Acquiring Alvogen’s operations in central and eastern Europe will strengthen private equity-backed Zentiva’s presence in both the generics and OTC markets.

Zentiva Strikes Deal To Buy UK’s Creo Pharmaceuticals As It Pursues ‘Champion’ Ambitions

Zentiva has announced it is buying the UK’s Creo Pharmaceuticals from Amneal Pharmaceuticals as it pursues its goal of becoming a European generics leader.

Zentiva Set To Acquire Romania's Solacium

Zentiva has signed its first acquisition after it was carved out from Sanofi last year to become an independent company, entering into a shared purchase agreement with Siyiara to acquire Romania-based food supplement and OTC medicines producer Solacium.

Related Content

Topics

UsernamePublicRestriction

Register

GB139992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel